



**TITLE: Care of Patients with Multiple Sclerosis: Guidelines**

**DATE:** 10 February 2012

## **RESEARCH QUESTION**

1. What are the evidence-based guidelines and recommendations for the full spectrum of care of patients with multiple sclerosis?

## **KEY MESSAGE**

Extensive evidence for the full spectrum of care of patients with multiple sclerosis was identified. Numerous treatment options exist for the different forms of multiple sclerosis and its associated co-morbidities. Limited evidence was identified pertaining to evidence-based guidelines and recommendations.

## **METHODS**

A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2012, Issue 1), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and abbreviated list of major international health technology agencies, as well as a focused Internet search. Filters were applied to limit the retrieval by health technology assessments, systematic reviews, meta-analyses and guidelines. The search was also limited to English language documents published between January 1, 2007 and January 30, 2012. Internet links were provided, where available.

## **RESULTS**

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by evidence-based guidelines.

Two health technology assessments, forty-six systematic reviews, and two evidence-based guidelines and recommendations were identified regarding the full spectrum of care of patients with multiple sclerosis. Additional references of potential interest are provided in the appendix.

**Disclaimer:** The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report.

**Copyright:** This report contains CADTH copyright material and may contain material in which a third party owns copyright. **This report may be used for the purposes of research or private study only.** It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner.

**Links:** This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners' own terms and conditions.

## Health Technology Assessments

### *Diagnosis*

1. Achten E, Deblaere K. Health technology assessment on the use of magnetic resonance imaging (MRI) and computed tomography (CT) in the diagnosis of multiple sclerosis (MS) and clinically isolated syndromes (CIS). *Eur J Radiol.* 2008 Feb;65(2):211-3.  
[PubMed: PM18164571](#)

### *Treatment*

2. Clar C, Velasco GM, Gericke C, Busse R. Interferons and natalizumab for multiple sclerosis. *GMS Health Technol Assess.* 2008;4:Doc09. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3011296>  
[PubMed: PM21289915](#)

## Systematic Reviews and Meta-analyses

### *Diagnosis*

3. Petzold A, de Boer JF, Schippling S, Vermersch P, Kardon R, Green A, et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. *Lancet Neurol.* 2010 Sep;9(9):921-32.  
[PubMed: PM20723847](#)

### *Treatment*

4. La ML, Vacchi L, Di PC, Ebers G, Rovaris M, Fredrikson S, et al. Interferon beta for secondary progressive multiple sclerosis. *Cochrane Database Syst Rev.* 2012;1:CD005181.  
[PubMed: PM22258960](#)
5. Andreasen AK, Stenager E, Dalgas U. The effect of exercise therapy on fatigue in multiple sclerosis. *Mult Scler.* 2011 Sep;17(9):1041-54.  
[PubMed: PM21467189](#)
6. Del SF, Maratea D, Fadda V, Trippoli S, Messori A. Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis. *Eur J Clin Pharmacol.* 2011 Nov 5.  
[PubMed: PM22057838](#)
7. He D, Zhou H, Guo D, Hao Z, Wu B. Pharmacologic treatment for memory disorder in multiple sclerosis. *Cochrane Database Syst Rev.* 2011;(10):CD008876.  
[PubMed: PM21975787](#)
8. He D, Zhou H, Han W, Zhang S. Rituximab for relapsing-remitting multiple sclerosis. *Cochrane Database Syst Rev.* 2011;12:CD009130.  
[PubMed: PM22161445](#)

9. Koch MW, Glazenborg A, Uyttenboogaart M, Mostert J, De KJ. Pharmacologic treatment of depression in multiple sclerosis. *Cochrane Database Syst Rev.* 2011;(2):CD007295.  
[PubMed: PM21328292](#)
10. Oliver BJ, Kohli E, Kasper LH. Interferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials. *J Neurol Sci.* 2011 Mar 15;302(1-2):96-105.  
[PubMed: PM21167504](#)
11. Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di PC, et al. Natalizumab for relapsing remitting multiple sclerosis. *Cochrane Database Syst Rev.* 2011;(10):CD007621.  
[PubMed: PM21975773](#)
12. Rae-Grant AD, Turner AP, Sloan A, Miller D, Hunziker J, Haselkorn JK. Self-management in neurological disorders: Systematic review of the literature and potential interventions in multiple sclerosis care. *J Rehabil Res Dev.* 2011;48(9):1087-100.  
[PubMed: PM22234713](#)
13. Reston JT, Uhl S, Treadwell JR, Nash RA, Schoelles K. Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review. *Mult Scler.* 2011 Feb;17(2):204-13.  
[PubMed: PM20921236](#)
14. Rice GPA, Incorvaia B, Munari LM, Ebers G, Polman C, D'Amico R, et al. Interferon in relapsing-remitting multiple sclerosis. *Cochrane Database Syst Rev.* 2009(1): CD002002. Abstract available from:  
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002002/abstract>
15. Rosti-Otajarvi EM, Hamalainen PI. Neuropsychological rehabilitation for multiple sclerosis. *Cochrane Database Syst Rev.* 2011;11:CD009131.  
[PubMed: PM22071863](#)
16. Wang J, Xiao Y, Luo M, Luo H. Statins for multiple sclerosis. *Cochrane Database Syst Rev.* 2011;12:CD008386.  
[PubMed: PM22161428](#)
17. Bennett M, Heard R. Hyperbaric oxygen therapy for multiple sclerosis. *CNS Neurosci Ther.* 2010 Apr;16(2):115-24.  
[PubMed: PM20415839](#)
18. Bronson C, Brewerton K, Ong J, Palanca C, Sullivan SJ. Does hippotherapy improve balance in persons with multiple sclerosis: a systematic review. *Eur J Phys Rehabil Med.* 2010 Sep;46(3):347-53.  
[PubMed: PM20927000](#)
19. Fan X. A meta-analysis of interferon-beta in the secondary progressive multiple sclerosis. *Zhonghua Yi Xue Za Zhi* 2009 Jun 2;89(21):1484-9. English abstract available: [PubMed: PM19953902](#)

20. Jagannath VA, Fedorowicz Z, Asokan GV, Robak EW, Whamond L. Vitamin D for the management of multiple sclerosis. *Cochrane Database Syst Rev.* 2010;(12):CD008422.  
[PubMed: PM21154396](#)
21. La ML, Munari LM, Lovati R. Glatiramer acetate for multiple sclerosis. *Cochrane Database Syst Rev.* 2010;(5):CD004678.  
[PubMed: PM20464733](#)
22. Liu J, Wang L, Zhan S, Tan J, Xia Y. Daclizumab for relapsing remitting multiple sclerosis. *Cochrane Database Syst Rev.* 2010;(6):CD008127.  
[PubMed: PM20556791](#)
23. Nikfar S, Rahimi R, Abdollahi M. A meta-analysis of the efficacy and tolerability of interferon-beta in multiple sclerosis, overall and by drug and disease type. *Clin Ther.* 2010 Oct;32(11):1871-88.  
[PubMed: PM21095482](#)
24. Rojas JI, Romano M, Ciapponi A, Patrucco L, Cristiano E. Interferon Beta for primary progressive multiple sclerosis. *Cochrane Database Syst Rev.* 2010;(1):CD006643.  
[PubMed: PM20091602](#)
25. Souza A, Kelleher A, Cooper R, Cooper RA, Iezzoni LI, Collins DM. Multiple sclerosis and mobility-related assistive technology: systematic review of literature. *J Rehabil Res Dev.* 2010;47(3):213-23.  
[PubMed: PM20665347](#)
26. Tejani AM, Wasdell M, Spiwak R, Rowell G, Nathwani S. Carnitine for fatigue in multiple sclerosis. *Cochrane Database Syst Rev.* 2010;(2):CD007280.  
[PubMed: PM20166093](#)
27. Wang J, Xiao Y, Luo M, Zhang X, Luo H. Statins for multiple sclerosis. *Cochrane Database Syst Rev.* 2010;(12):CD008386.  
[PubMed: PM21154395](#)
28. Burton JM, O'Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. *Cochrane Database Syst Rev.* 2009;(3):CD006921.  
[PubMed: PM19588409](#)
29. Khan F, Ng L, Turner-Stokes L. Effectiveness of vocational rehabilitation intervention on the return to work and employment of persons with multiple sclerosis. *Cochrane Database Syst Rev.* 2009;(1):CD007256.  
[PubMed: PM19160331](#)
30. Koch MW, Polman SK, Uyttenboogaart M, De KJ. Treatment of seizures in multiple sclerosis. *Cochrane Database Syst Rev.* 2009;(3):CD007150.  
[PubMed: PM19588420](#)

31. Lakhan SE, Rowland M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. *BMC Neurol.* 2009;9:59. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793241>  
[PubMed: PM19961570](#)
32. Nicholas R, Chataway J. Multiple sclerosis. *Clin Evid (Online).* 2009.  
[PubMed: PM21733201](#)
33. Nicholas RS, Friede T, Hollis S, Young CA. Anticholinergics for urinary symptoms in multiple sclerosis. *Cochrane Database Syst Rev.* 2009;(1):CD004193.  
[PubMed: PM19160231](#)
34. Snook EM, Motl RW. Effect of exercise training on walking mobility in multiple sclerosis: a meta-analysis. *Neurorehabil Neural Repair.* 2009 Feb;23(2):108-16.  
[PubMed: PM18948413](#)
35. Ciccone A, Beretta S, Brusafferri F, Galea I, Protti A, Spreafico C. Corticosteroids for the long-term treatment in multiple sclerosis. *Cochrane Database Syst Rev.* 2008;(1):CD006264.  
[PubMed: PM18254098](#)
36. Clerico M, Faggiano F, Palace J, Rice G, Tintore M, Durelli L. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. *Cochrane Database Syst Rev.* 2008;(2):CD005278.  
[PubMed: PM18425915](#)
37. Lee D, Newell R, Ziegler L, Topping A. Treatment of fatigue in multiple sclerosis: a systematic review of the literature. *Int J Nurs Pract.* 2008 Apr;14(2):81-93.  
[PubMed: PM18315820](#)
38. MacDonald R, Monga M, Fink HA, Wilt TJ. Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects. *J Spinal Cord Med.* 2008;31(2):157-65. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2565485>  
[PubMed: PM18581662](#)
39. Melo A, Rodrigues B, Bar-Or A. Beta interferons in clinically isolated syndromes: a meta-analysis. *Arq Neuropsiquiatr.* 2008 Mar;66(1):8-10.  
[PubMed: PM18392405](#)
40. Motl RW, Gosney JL. Effect of exercise training on quality of life in multiple sclerosis: a meta-analysis. *Mult Scler.* 2008 Jan;14(1):129-35.  
[PubMed: PM17881388](#)
41. Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis. *Cochrane Database Syst Rev.* 2007;(4):CD003982.  
[PubMed: PM17943809](#)

42. Farinotti M, Simi S, Di PC, McDowell N, Brait L, Lupo D, et al. Dietary interventions for multiple sclerosis. Cochrane Database Syst Rev. 2007;(1):CD004192.  
[PubMed: PM17253500](#)
43. Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin. 2007 Jan;23(1):17-24.  
[PubMed: PM17257464](#)
44. Khan F, Turner-Stokes L, Ng L, Kilpatrick T. Multidisciplinary rehabilitation for adults with multiple sclerosis. Cochrane Database Syst Rev. 2007;(2):CD006036.  
[PubMed: PM17443610](#)
45. La ML, Milanese C, Mascoli N, D'Amico R, Weinstock-Guttman B. Cyclophosphamide for multiple sclerosis. Cochrane Database Syst Rev. 2007;(1):CD002819.  
[PubMed: PM17253481](#)
46. Mills RJ, Yap L, Young CA. Treatment for ataxia in multiple sclerosis. Cochrane Database Syst Rev. 2007;(1):CD005029.  
[PubMed: PM17253537](#)
47. Nicholas R, Chataway J. Multiple sclerosis. Clin Evid (Online). 2007;2007. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907805>  
[PubMed: PM19454107](#)
48. Pucci E, Branas P, D'Amico R, Giuliani G, Solari A, Taus C. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2007;(1):CD002818.  
[PubMed: PM17253480](#)

### Guidelines and Recommendations

49. National Guideline Clearinghouse [Internet]. Rockville (MD): National Guideline Clearinghouse; c2009-. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines; 2010 [updated] [cited 2012 Feb 09]. NGC summary available from:  
<http://www.guideline.gov/content.aspx?id=4099&search=multiple+sclerosis>
50. National Guideline Clearinghouse [Internet]. Rockville (MD): National Guideline Clearinghouse; c2009-. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; 2010 [updated] [cited 2012 Feb 09]. NGC summary available from:  
<http://www.guideline.gov/content.aspx?id=24497&search=multiple+sclerosis>

### PREPARED BY:

Canadian Agency for Drugs and Technologies in Health

Tel: 1-866-898-8439

[www.cadth.ca](http://www.cadth.ca)

**APPENDIX – FURTHER INFORMATION:****Reviews and Recommendations (methodology not specified)**

51. Fernandez O, Garcia-Merino JA, Arroyo R, varez-Cermeno JC, Arbizu T, Izquierdo G, et al. Spanish consensus on the use of natalizumab (Tysabri((R))) - 2011. *Neurologia*. 2011 Nov 9.  
[PubMed: PM22078648](#)
52. George B. Regulations and guidelines governing stem cell based products: Clinical considerations. *Perspect Clin Res*. 2011 Jul;2(3):94-9. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159216>  
[PubMed: PM21897884](#)
53. Ghezzi A, Carone R, Del PG, Amato MP, Bertolotto A, Comola M, et al. Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple sclerosis Study Group. *Neurol Sci*. 2011 Dec;32(6):1223-31.  
[PubMed: PM21948057](#)
54. Ghezzi A, Grimaldi LM, Marrosu MG, Pozzilli C, Comi G, Bertolotto A, et al. Natalizumab therapy of multiple sclerosis: recommendations of the Multiple sclerosis Study Group--Italian Neurological Society. *Neurol Sci*. 2011 Apr;32(2):351-8.  
[PubMed: PM21234775](#)
55. Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. *Lancet Neurol*. 2011 Aug;10(8):745-58.  
[PubMed: PM21777829](#)
56. Langdon D, Amato M, Boringa J, Brochet B, Foley F, Fredrikson S, et al. Recommendations for a Brief International Cognitive Assessment for Multiple sclerosis (BICAMS). *Mult Scler*. 2011 Dec 21.  
[PubMed: PM22190573](#)
57. Miravalle AA. Guidelines and best practices for appropriate use of dalfampridine in managed care populations. *Am J Manag Care*. 2011 May;17 Suppl 5 Improving:S154-S160.  
[PubMed: PM21761954](#)
58. Foley J. Recommendations for the selection, treatment, and management of patients utilizing natalizumab therapy for multiple sclerosis. *Am J Manag Care*. 2010 Jun;16(6 Suppl):S178-S183.  
[PubMed: PM20615054](#)
59. Lovblad KO, Anzalone N, Dorfler A, Essig M, Hurwitz B, Kappos L, et al. MR imaging in multiple sclerosis: review and recommendations for current practice. *AJNR Am J Neuroradiol*. 2010 Jun;31(6):983-9.  
[PubMed: PM20019103](#)

60. Namey M, Halper J, O'leary S, Beavin J, Bishop C. Best practices in multiple sclerosis: infusion reactions versus hypersensitivity associated with biologic therapies. *J Infus Nurs.* 2010 Mar;33(2):98-111.  
[PubMed: PM20228647](#)
61. Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis [Internet]. London: National Institute for Health and Clinical Excellence (NICE); 2010 [cited 2012 Feb 09]. (NICE technology appraisal guidance 127). Available from: <http://www.nice.org.uk/nicemedia/live/11822/36136/36136.pdf>
62. Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. *Lancet Neurol.* 2010 Jul;9(7):740-50.  
[PubMed: PM20610349](#)
63. Solomon AJ, Whitham RH. Multiple sclerosis and vitamin D: a review and recommendations. *Curr Neurol Neurosci Rep.* 2010 Sep;10(5):389-96.  
[PubMed: PM20556546](#)
64. Berger T. Current therapeutic recommendations in multiple sclerosis. *J Neurol Sci.* 2009 Dec;287 Suppl 1:S37-S45.  
[PubMed: PM20106347](#)
65. Fowler CJ, Panicker JN, Drake M, Harris C, Harrison SC, Kirby M, et al. A UK consensus on the management of the bladder in multiple sclerosis. *Postgrad Med J.* 2009 Oct;85(1008):552-9.  
[PubMed: PM19789195](#)
66. Klingel R, Heibges A, Fassbender C. Plasma exchange and immunoadsorption for autoimmune neurologic diseases - current guidelines and future perspectives. *Atheroscler Suppl.* 2009 Dec 29;10(5):129-32.  
[PubMed: PM20129391](#)
67. Multiple sclerosis Therapy Consensus Group (MSTCG), Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. *J Neurol.* 2008 Oct;255(10):1449-63.  
[PubMed: PM19005625](#)
68. Boster A, Edan G, Frohman E, Javed A, Stuve O, Tselis A, et al. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. *Lancet Neurol.* 2008 Feb;7(2):173-83.  
[PubMed: PM18207115](#)
69. Dalgas U, Stenager E, Ingemann-Hansen T. Multiple sclerosis and physical exercise: recommendations for the application of resistance-, endurance- and combined training. *Mult Scler.* 2008 Jan;14(1):35-53.  
[PubMed: PM17881393](#)

70. de SN, Filippi M, Miller D, Pouwels PJ, Rovira A, Gass A, et al. Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. *Neurology*. 2007 Nov 13;69(20):1942-52.  
[PubMed: PM17998486](#)
71. Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. *Lancet Neurol*. 2007 May;6(5):431-41.  
[PubMed: PM17434098](#)
72. Nielsen JM, Korteweg T, Polman CH. Diagnosing MS: recent guidelines and future goals focusing on magnetic resonance imaging. *Int MS J*. 2007 Mar;14(1):29-34.  
[PubMed: PM17509251](#)

### CADTH reports

73. Canadian Agency for Drugs and Technologies in Health (CADTH). Investigating chronic cerebrospinal venous insufficiency for the treatment of multiple sclerosis (environmental scan) [Internet]. Ottawa: CADTH; 2010 [cited 2012 Feb 09]. Available from :  
[http://www.cadth.ca/media/pdf/Chronic\\_Cerebrospinal\\_Venous\\_Insufficiency\\_MS\\_es-15\\_e.pdf](http://www.cadth.ca/media/pdf/Chronic_Cerebrospinal_Venous_Insufficiency_MS_es-15_e.pdf) **Updated version:** [http://www.cadth.ca/media/pdf/MS\\_Liberation\\_Update\\_es-20\\_e.pdf](http://www.cadth.ca/media/pdf/MS_Liberation_Update_es-20_e.pdf)
74. Canadian Agency for Drugs and Technologies in Health (CADTH). Range of motion therapy for patients with multiple sclerosis: clinical effectiveness and guidelines [Internet]. Ottawa: CADTH; 2010 [cited 2012 Feb 09]. Available from :  
[http://www.cadth.ca/media/pdf/i0457\\_range\\_motion\\_patients\\_with\\_ms\\_htis-2.pdf](http://www.cadth.ca/media/pdf/i0457_range_motion_patients_with_ms_htis-2.pdf)